• 1. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol: A Comprehensive Overview

4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol is a compound with the CAS registry number 1391052-04-2, representing a significant advancement in the field of pharmaceutical chemistry. This compound is a derivative of salmeterol, a well-known long-acting β?-adrenergic receptor agonist, which is widely used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). The structural modifications introduced in this compound aim to enhance its pharmacokinetic properties, bioavailability, and therapeutic efficacy while minimizing potential side effects.

The molecular structure of 4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol incorporates several key functional groups that contribute to its unique pharmacological profile. The presence of hydroxyl (-OH) and hydroxymethyl (-CH?OH) groups introduces hydrophilic characteristics, which may influence the compound's solubility and absorption properties. Additionally, the phenylethyl group serves as a critical structural element, potentially enhancing the molecule's ability to interact with β?-adrenergic receptors. Recent studies have highlighted the importance of such structural modifications in improving receptor binding affinity and selectivity, thereby optimizing therapeutic outcomes.

Recent research has focused on the in vitro and in vivo evaluation of 4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol, with particular emphasis on its pharmacokinetics and pharmacodynamics. Preclinical studies have demonstrated that this compound exhibits enhanced lung deposition efficiency compared to conventional salmeterol formulations, suggesting potential improvements in therapeutic efficacy. Furthermore, studies on its metabolic pathways have revealed that the hydroxylated groups may facilitate hepatic clearance, reducing systemic exposure and minimizing adverse effects associated with long-term use.

The development of 4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol represents a strategic approach to address some of the limitations associated with existing β?-adrenergic receptor agonists. For instance, traditional salmeterol formulations are often associated with issues such as rapid systemic absorption and potential cardiovascular side effects. By modifying the molecular structure to include hydrophilic groups, researchers aim to achieve a more localized effect within the respiratory system, thereby enhancing safety profiles while maintaining therapeutic efficacy.

From an industrial perspective, the synthesis of 4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol involves a multi-step chemical process that requires precise control over reaction conditions to ensure optimal yields and product quality. The incorporation of hydroxyl and hydroxymethyl groups necessitates the use of advanced synthetic techniques, including nucleophilic substitution and oxidation reactions. Recent advancements in catalytic processes have further streamlined these steps, making large-scale production more feasible and cost-effective.

In terms of regulatory considerations, 4-O-2-Hydroxy-2-4-Hydroxy-3-(Hydroxymethyl)Phenylethyl Salmeterol must undergo rigorous testing to meet global pharmaceutical standards. This includes extensive preclinical trials to assess safety profiles, as well as clinical trials to evaluate efficacy in human subjects. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive data on pharmacokinetics, toxicity, and long-term safety before granting approval for commercial use.

Looking ahead, the potential applications of 4-O-2-Hydroxy

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)